focus -WSS

focus

author：focus 2025-10-02 13:48:47 - browse：46

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Healthy food access boosts outcomes in two studies

Wikipedia

focus

WSS

First transplant of an entire human eye performed

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Carbon Health diabetes program, a test of data

How Vertex's cystic fibrosis drug is changing patients' lives

Senate HELP committee spars over health care workforce policies

hotspot

focus

hotspot

Activists slam private health insurers over coverage restrictions

Cancer diagnosis changes perspective doctor, former hospital CEO

As demand for Covid shots wanes, Moderna seeks its next success

Healthy food access boosts outcomes in two studies

Malaria cases in Florida and Texas: Here’s what you need to know

CDC's new outbreak response network to include Northeastern

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Today's health inequities arise from racist U.S. history, say experts

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Second xenotransplant done with gene

explore

EpiPen alternative approval delay highlights citizen petition issue

First transplant of an entire human eye performed

Why are Kaiser Permanente staff considering a strike?

Readout Newsletter: Zepbound, Valneva's vaccine, and more

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

leisure time

Wikipedia

focus

focus